A Jeff Aronin startup quietly yanks its IPO as the biotech market ends year on a whimper
Close to 6 months after it initially posted its S-1 in what was still a thriving biotech IPO market, Castle Creek Biosciences has now yanked the offering as new deals fade against the background of a hard, year-end appraisal for drug stocks.
In its filing with the SEC, Castle Creek CEO Matthew Gantz merely states that the biotech is no longer pursuing an IPO. He had initially penciled in a $100 million raise last summer.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 147,700+ biopharma pros reading Endpoints daily — and it's free.